For research use only. Not for therapeutic Use.
Fabomotizole(CAT: I002257) is a selective anxiolytic agent that functions primarily by modulating the sigma-1 receptor and MT₃ (melatonin) receptor, contributing to its neuroprotective and anti-anxiety effects. Unlike traditional benzodiazepines, Fabomotizole does not cause sedation, dependence, or withdrawal symptoms. It also stabilizes GABAergic and glutamatergic neurotransmission and protects neurons from oxidative stress and apoptosis. Fabomotizole is widely studied in neuropharmacology for its potential in treating generalized anxiety disorder (GAD) and stress-related neurological conditions. Its unique mechanism of action makes it a promising candidate for developing safer, non-sedative anxiolytic therapies.
| Catalog Number | I002257 |
| CAS Number | 173352-21-1 |
| Molecular Formula | C15H21N3O2S |
| Purity | ≥95% |
| Target | anxiolytic agent |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine |
| InChI | InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17) |
| InChIKey | WWNUCVSRRUDYPP-UHFFFAOYSA-N |
| SMILES | CCOC1=CC=C2C(N=C(SCCN3CCOCC3)N2)=C1 |
